Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gynecology

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    February 2025
  1. VAN DIJK D, Vermij L, Leon-Castillo A, Powell M, et al
    Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.
    J Clin Oncol. 2025;43:443-452.
    PubMed     Abstract available


    January 2025
  2. SLOMOVITZ BM, Cibula D, Lv W, Ortac F, et al
    Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.
    J Clin Oncol. 2025;43:251-259.
    PubMed     Abstract available


  3. CHEHADE R, Jerzak KJ, Tavanger F, Plotkin A, et al
    Advances in Vulvar Cancer Biology and Management.
    J Clin Oncol. 2025;43:89-100.
    PubMed     Abstract available


    October 2024
  4. CHLEBOWSKI RT, Aragaki AK, Pan K, Haque R, et al
    Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
    J Clin Oncol. 2024;42:3537-3549.
    PubMed     Abstract available


  5. BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al
    Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
    J Clin Oncol. 2024;42:3550-3560.
    PubMed     Abstract available


  6. SANTIN AD, Corr BR, Spira A, Willmott L, et al
    Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
    J Clin Oncol. 2024;42:3421-3429.
    PubMed     Abstract available


  7. LEE JM, Brady MF, Miller A, Moore RG, et al
    Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
    J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
    PubMed     Abstract available


  8. FERGUSON SE, Brotto LA, Kwon J, Samouelian V, et al
    Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.
    J Clin Oncol. 2024 Oct 1:JCO2400440. doi: 10.1200/JCO.24.00440.
    PubMed     Abstract available


    September 2024
  9. GONZALEZ-MARTIN A, Rubio MJ, Heitz F, Depont Christensen R, et al
    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
    J Clin Oncol. 2024 Sep 18:JCO2400668. doi: 10.1200/JCO.24.00668.
    PubMed     Abstract available


    August 2024
  10. BERCOW A, Del Carmen MG, Rauh-Hain JA, Melamed A, et al
    Role of Minimally Invasive Techniques in the Management of Early-Stage Carcinoma of the Uterine Cervix.
    J Clin Oncol. 2024;42:2731-2735.
    PubMed     Abstract available


  11. FELLON CM, Elsensohn AN, Kraus CN, Virgen CA, et al
    Vulvar Squamous Cell Carcinoma Guidelines May Benefit From Consideration of Tissue-Sparing Techniques as Treatment Options.
    J Clin Oncol. 2024;42:2723-2724.
    PubMed    


  12. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
    Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
    J Clin Oncol. 2024;42:2645-2659.
    PubMed     Abstract available


    July 2024
  13. KLOPP AH, Enserro D, Powell M, Randall M, et al
    Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.
    J Clin Oncol. 2024;42:2425-2435.
    PubMed     Abstract available


    June 2024
  14. HOROWITZ NS, Deng W, Peterson I, Mannel RS, et al
    Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
    J Clin Oncol. 2024;42:1914-1921.
    PubMed     Abstract available


    May 2024
  15. RAMIREZ PT, Robledo KP, Frumovitz M, Pareja R, et al
    LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.
    J Clin Oncol. 2024 May 29:JCO2302335. doi: 10.1200/JCO.23.02335.
    PubMed     Abstract available


  16. LANDEN CN, Buckanovich RJ, Sill MW, Mannel RS, et al
    Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
    J Clin Oncol. 2024 May 22:JCO2302076. doi: 10.1200/JCO.23.02076.
    PubMed     Abstract available


  17. HARRIS HR, Davis CP, Terry KL
    Epidemiologic Methods to Advance Our Understanding of Ovarian Cancer Risk.
    J Clin Oncol. 2024 May 15:JCO2400602. doi: 10.1200/JCO.24.00602.
    PubMed    


    April 2024
  18. MUTLU SUTCUOGLU B, Sutcuoglu O
    Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
    J Clin Oncol. 2024;42:1204-1205.
    PubMed    


  19. HAN CY, Lu KH, Corrigan G, Perez A, et al
    Normal Risk Ovarian Screening Study: 21-Year Update.
    J Clin Oncol. 2024;42:1102-1109.
    PubMed     Abstract available


    March 2024
  20. CHARGARI C, Wasserman J, Gabro A, Canlobre G, et al
    Vulvar Carcinoma: Standard of Care and Perspectives.
    J Clin Oncol. 2024;42:961-972.
    PubMed     Abstract available


  21. LUO PH, Mo DC, Wang HL, Liang XJ, et al
    Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab.
    J Clin Oncol. 2024 Mar 7:JCO2302479. doi: 10.1200/JCO.23.02479.
    PubMed    


    February 2024
  22. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
    Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
    J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
    PubMed     Abstract available


  23. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    PubMed    


    January 2024
  24. WESTIN SN, Moore K, Chon HS, Lee JY, et al
    Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
    J Clin Oncol. 2024;42:283-299.
    PubMed     Abstract available


  25. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
    Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
    J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
    PubMed     Abstract available


  26. PIJNENBORG JMA, van Weelden WJ, Reijnen C, Xanthoulea S, et al
    Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification.
    J Clin Oncol. 2024;42:8-12.
    PubMed    


    December 2023
  27. VERGOTE I, Perez-Fidalgo JA, Hamilton EP, Valabrega G, et al
    Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
    J Clin Oncol. 2023;41:5400-5410.
    PubMed     Abstract available


    November 2023
  28. HAN K, Zou J, Zhao Z, Baskurt Z, et al
    Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
    J Clin Oncol. 2023 Nov 16:JCO2300954. doi: 10.1200/JCO.23.00954.
    PubMed     Abstract available


  29. LAVERY JA, Boutros PC, Scott JM, Tammela T, et al
    Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.
    J Clin Oncol. 2023;41:4982-4992.
    PubMed     Abstract available


  30. MONK BJ, Colombo N, Tewari KS, Dubot C, et al
    First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
    J Clin Oncol. 2023 Nov 1:JCO2300914. doi: 10.1200/JCO.23.00914.
    PubMed     Abstract available


  31. ST LAURENT J, Liu JF
    Treatment Approaches for Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Nov 1:JCO2301771. doi: 10.1200/JCO.23.01771.
    PubMed     Abstract available


    October 2023
  32. AREND RC, Monk BJ, Shapira-Frommer R, Haggerty AF, et al
    Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
    J Clin Oncol. 2023 Oct 31:JCO2202915. doi: 10.1200/JCO.22.02915.
    PubMed     Abstract available


  33. FLEMING GF
    Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer.
    J Clin Oncol. 2023;41:4603-4604.
    PubMed    


    September 2023
  34. HOREWEG N, Nout RA, Jurgenliemk-Schulz IM, Lutgens LCHW, et al
    Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
    J Clin Oncol. 2023;41:4369-4380.
    PubMed     Abstract available


  35. SPRIGGS DR, Fleming GF
    Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer.
    J Clin Oncol. 2023;41:4063-4064.
    PubMed    


  36. INGHAM M, Allred JB, Chen L, Das B, et al
    Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
    J Clin Oncol. 2023;41:4154-4163.
    PubMed     Abstract available


  37. KENTER GG, Greggi S, Vergote I, Katsaros D, et al
    Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.
    J Clin Oncol. 2023 Sep 1:JCO2202852. doi: 10.1200/JCO.22.02852.
    PubMed     Abstract available


    August 2023
  38. VERGOTE I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, et al
    Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    J Clin Oncol. 2023 Aug 31:JCO2300720. doi: 10.1200/JCO.23.00720.
    PubMed     Abstract available


  39. KURTZ JE, Pujade-Lauraine E, Oaknin A, Belin L, et al
    Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
    J Clin Oncol. 2023 Aug 29:JCO2300529. doi: 10.1200/JCO.23.00529.
    PubMed     Abstract available


    June 2023
  40. COLOMBO N, Van Gorp T, Matulonis UA, Oaknin A, et al
    Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
    J Clin Oncol. 2023 Jun 26:JCO2202624. doi: 10.1200/JCO.22.02624.
    PubMed     Abstract available


  41. ZHANG X, Elsaid MI, DeGraffinreid C, Champion VL, et al
    Impact of the COVID-19 Pandemic on Cancer Screening Delays.
    J Clin Oncol. 2023;41:3194-3202.
    PubMed     Abstract available


  42. MAKKER V, Colombo N, Herraez AC, Monk BJ, et al
    Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
    J Clin Oncol. 2023;41:2904-2910.
    PubMed     Abstract available


    May 2023
  43. NISHIKAWA T, Hasegawa K, Matsumoto K, Mori M, et al
    Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
    J Clin Oncol. 2023;41:2789-2799.
    PubMed     Abstract available


  44. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    PubMed     Abstract available


  45. STROOT IAS, Brouwer J, Bart J, Hollema H, et al
    High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.
    J Clin Oncol. 2023;41:2523-2535.
    PubMed     Abstract available


  46. BERNSTEIN E, Lev-Ari S, Shapira S, Leshno A, et al
    Data From a One-Stop-Shop Comprehensive Cancer Screening Center.
    J Clin Oncol. 2023;41:2503-2510.
    PubMed     Abstract available


    April 2023
  47. REYNOLDS AC, McKenzie LJ
    Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.
    J Clin Oncol. 2023;41:2281-2292.
    PubMed     Abstract available


    March 2023
  48. FU S, Yao S, Yuan Y, Previs RA, et al
    Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
    J Clin Oncol. 2023;41:1725-1734.
    PubMed     Abstract available


  49. VIDRINE JI, Sutton SK, Wetter DW, Shih YT, et al
    Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2023 Mar 15:JCO2201228. doi: 10.1200/JCO.22.01228.
    PubMed     Abstract available


    February 2023
  50. MAKKER V, Aghajanian C, Cohn AL, Romeo M, et al
    A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
    J Clin Oncol. 2023;41:974-979.
    PubMed     Abstract available


  51. SUN R, Huang B, Wei LJ
    Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer.
    J Clin Oncol. 2023 Feb 10:JCO2202596. doi: 10.1200/JCO.22.02596.
    PubMed    


    January 2023
  52. MATULONIS UA, Lorusso D, Oaknin A, Pignata S, et al
    Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
    J Clin Oncol. 2023 Jan 30:JCO2201900. doi: 10.1200/JCO.22.01900.
    PubMed     Abstract available


  53. KONSTANTINOPOULOS PA, Lee EK, Xiong N, Krasner C, et al
    A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
    J Clin Oncol. 2023;41:599-608.
    PubMed     Abstract available


  54. CASTLE PE, Wentzensen N
    Clarifying the Equivocal Diagnosis of Cervical Intraepithelial Neoplasia 2: Still a Work in Progress.
    J Clin Oncol. 2023;41:419-420.
    PubMed    


  55. SCHMID MP, Lindegaard JC, Mahantshetty U, Tanderup K, et al
    Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.
    J Clin Oncol. 2023 Jan 4:JCO2201096. doi: 10.1200/JCO.22.01096.
    PubMed     Abstract available


  56. CRABB SJ, Hussain S, Soulis E, Hinsley S, et al
    A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:54-64.
    PubMed     Abstract available


  57. YOU B, Sehgal V, Hosmane B, Huang X, et al
    CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    J Clin Oncol. 2023;41:107-116.
    PubMed     Abstract available


    December 2022
  58. KINDLER HL, Hammel P, Reni M, Van Cutsem E, et al
    Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    J Clin Oncol. 2022;40:3929-3939.
    PubMed     Abstract available


  59. COHEN CM, Wentzensen N, Castle PE, Schiffman M, et al
    Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype.
    J Clin Oncol. 2022 Dec 1:JCO2201424. doi: 10.1200/JCO.22.01424.
    PubMed     Abstract available


    November 2022
  60. BEAVIS AL, Fader AN
    Surveillance Strategies in Endometrial Cancer Care: Why Less Represents Progress.
    J Clin Oncol. 2022;40:3790-3795.
    PubMed    


  61. HERZOG C, Marin F, Jones A, Evans I, et al
    A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.
    J Clin Oncol. 2022;40:3828-3838.
    PubMed     Abstract available


  62. ZOLA P, Ciccone G, Piovano E, Fuso L, et al
    Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial.
    J Clin Oncol. 2022;40:3817-3827.
    PubMed     Abstract available


  63. ZHANG J, Liu M
    Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.
    J Clin Oncol. 2022;40:3783.
    PubMed    


  64. PFISTERER J, Joly F, Kristensen G, Rau J, et al
    Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
    J Clin Oncol. 2022 Nov 4:JCO2201010. doi: 10.1200/JCO.22.01010.
    PubMed     Abstract available


    October 2022
  65. YOU B, Purdy C, Copeland LJ, Swisher EM, et al
    Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
    J Clin Oncol. 2022 Oct 17:JCO2201207. doi: 10.1200/JCO.22.01207.
    PubMed     Abstract available


  66. MARCHETTI C, Fagotti A, Scambia G
    Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
    J Clin Oncol. 2022 Oct 6:JCO2201585. doi: 10.1200/JCO.22.01585.
    PubMed    


  67. THIEL KW, Devor EJ, Filiaci VL, Mutch D, et al
    TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    J Clin Oncol. 2022;40:3289-3300.
    PubMed     Abstract available


    September 2022
  68. TEW WP, Lacchetti C, Kohn EC
    Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Sep 23:JCO2201934. doi: 10.1200/JCO.22.01934.
    PubMed     Abstract available


  69. KREMER WW, Dick S, Heideman DAM, Steenbergen RDM, et al
    Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4/miR124-2 DNA Methylation (CONCERVE Study).
    J Clin Oncol. 2022;40:3037-3046.
    PubMed     Abstract available


  70. DISILVESTRO P, Banerjee S, Colombo N, Scambia G, et al
    Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
    J Clin Oncol. 2022 Sep 9:JCO2201549. doi: 10.1200/JCO.22.01549.
    PubMed     Abstract available


  71. TANYI JL, Randall LM, Chambers SK, Butler KA, et al
    A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
    J Clin Oncol. 2022 Sep 7:JCO2200291. doi: 10.1200/JCO.22.00291.
    PubMed     Abstract available


    August 2022
  72. SPILSBURY K, Tuesley KM, Pearson SA, Coory MD, et al
    Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions.
    J Clin Oncol. 2022 Aug 24:JCO2200097. doi: 10.1200/JCO.22.00097.
    PubMed     Abstract available


  73. HAMPEL H, Yurgelun MB
    Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
    J Clin Oncol. 2022;40:2681-2692.
    PubMed     Abstract available


  74. FU S, Corr BR, Culm-Merdek K, Mockbee C, et al
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
    J Clin Oncol. 2022;40:2568-2577.
    PubMed     Abstract available


  75. LI N, Zhang Y, Wang J, Zhu J, et al
    Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    J Clin Oncol. 2022;40:2436-2446.
    PubMed     Abstract available


    July 2022
  76. HURWITZ LM, Townsend MK, Jordan SJ, Patel AV, et al
    Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
    J Clin Oncol. 2022 Jul 22:JCO2101900. doi: 10.1200/JCO.21.01900.
    PubMed     Abstract available


  77. GEBSKI V, Obermair A, Janda M
    Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinical Important Differences and QoL Profiles.
    J Clin Oncol. 2022;40:2378-2388.
    PubMed     Abstract available


  78. BETANCOURT NJ, Qian MF, Pickford JR, Bailey-Healy I, et al
    Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity.
    J Clin Oncol. 2022;40:2119-2127.
    PubMed     Abstract available


    June 2022
  79. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    


  80. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available


  81. MONK BJ, Parkinson C, Lim MC, O'Malley DM, et al
    A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
    J Clin Oncol. 2022 Jun 6:JCO2201003. doi: 10.1200/JCO.22.01003.
    PubMed     Abstract available


    May 2022
  82. HARPER DM
    Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status.
    J Clin Oncol. 2022 May 20:JCO2200609. doi: 10.1200/JCO.22.00609.
    PubMed    


  83. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    


  84. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    


  85. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available


  86. DONOVAN HS, Sereika SM, Wenzel LB, Edwards RP, et al
    Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).
    J Clin Oncol. 2022;40:1464-1473.
    PubMed     Abstract available


    April 2022
  87. ASLAN V, Sutcuoglu O, Ozet A, Ozdemir N, et al
    Abscobal Effect of Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer.
    J Clin Oncol. 2022 Apr 29:JCO2200084. doi: 10.1200/JCO.22.00084.
    PubMed    


  88. ACHARYA S
    A View on the PARCER Trial.
    J Clin Oncol. 2022;40:1130.
    PubMed    


  89. CHOPRA S, Kannan S, Gupta S
    Reply to S. Acharya.
    J Clin Oncol. 2022;40:1130-1131.
    PubMed    


    March 2022
  90. ROQUE DR, Matei D
    Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion.
    J Clin Oncol. 2022;40:924-926.
    PubMed    


  91. POWELL MA, Filiaci VL, Hensley ML, Huang HQ, et al
    Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
    J Clin Oncol. 2022;40:968-977.
    PubMed     Abstract available


  92. LIU JF, Brady MF, Matulonis UA, Miller A, et al
    Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
    J Clin Oncol. 2022 Mar 15:JCO2102011. doi: 10.1200/JCO.21.02011.
    PubMed     Abstract available


  93. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available


  94. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    J Clin Oncol. 2022;40:752-761.
    PubMed     Abstract available


    February 2022
  95. XU Q, Wang J, Sun Y, Lin Y, et al
    Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
    J Clin Oncol. 2022 Feb 22:JCO2102091. doi: 10.1200/JCO.21.02091.
    PubMed     Abstract available


  96. BAEK MH, Park EY, Ha HI, Park SY, et al
    Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.
    J Clin Oncol. 2022 Feb 21:JCO2102085. doi: 10.1200/JCO.21.02085.
    PubMed     Abstract available


  97. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
    Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
    PubMed     Abstract available


    January 2022
  98. LEI J, Arroyo-Muhr LS, Lagheden C, Eklund C, et al
    Human Papillomavirus Infection Determines Prognosis in Cervical Cancer.
    J Clin Oncol. 2022 Jan 25:JCO2101930. doi: 10.1200/JCO.21.01930.
    PubMed     Abstract available


  99. BILASH T, Walker LM
    Spare Parts: Navigating Ovarian Cancer as a Transgender Man.
    J Clin Oncol. 2022 Jan 12:JCO2101249. doi: 10.1200/JCO.21.01249.
    PubMed    


    December 2021
  100. O'MALLEY DM, Neffa M, Monk BJ, Melkadze T, et al
    Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
    J Clin Oncol. 2021 Dec 21:JCO2102067. doi: 10.1200/JCO.21.02067.
    PubMed     Abstract available


  101. MO DC, Ren T
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2021 Dec 10:JCO2102208. doi: 10.1200/JCO.21.02208.
    PubMed    


    November 2021
  102. OONK MHM, Slomovitz B, Baldwin PJW, van Doorn HC, et al
    Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
    J Clin Oncol. 2021;39:3623-3632.
    PubMed     Abstract available


    September 2021
  103. PORTER RL, Matulonis UA
    Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.
    J Clin Oncol. 2021 Sep 16:JCO2101886. doi: 10.1200/JCO.21.01886.
    PubMed    


  104. CHOPRA S, Gupta S, Kannan S, Dora T, et al
    Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.
    J Clin Oncol. 2021 Sep 10:JCO2002530. doi: 10.1200/JCO.20.02530.
    PubMed     Abstract available


  105. HAMANISHI J, Takeshima N, Katsumata N, Ushijima K, et al
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334.
    PubMed     Abstract available


    May 2021
  106. ZIVANOVIC O, Chi DS, Zhou Q, Iasonos A, et al
    Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    J Clin Oncol. 2021 May 21:JCO2100605. doi: 10.1200/JCO.21.00605.
    PubMed     Abstract available


  107. MADARIAGA A, Oza AM
    Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging Disease.
    J Clin Oncol. 2021;39:1513-1517.
    PubMed    


  108. LIU JF, Xiong N, Campos SM, Wright AA, et al
    Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
    J Clin Oncol. 2021;39:1531-1539.
    PubMed     Abstract available


    April 2021
  109. KONSTANTINOPOULOS PA, Cannistra SA
    Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
    J Clin Oncol. 2021 Apr 23:JCO2100571. doi: 10.1200/JCO.21.00571.
    PubMed    


  110. MOORE KN, Bookman M, Sehouli J, Miller A, et al
    Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    J Clin Oncol. 2021 Apr 23:JCO2100306. doi: 10.1200/JCO.21.00306.
    PubMed     Abstract available


    February 2021
  111. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.